Carbylan Therapeutics, Inc. 4
4 · Carbylan Therapeutics, Inc. · Filed Dec 31, 2015
Insider Transaction Report
Form 4
Renzi David
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Common Stock
2015-12-30$0.56/sh+10,000$5,600→ 10,000 total - Sale
Common Stock
2015-12-30$3.70/sh−10,000$37,000→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2015-12-30−10,000→ 515,825 totalExercise: $0.56Exp: 2023-06-06→ Common Stock (10,000 underlying)
Footnotes (3)
- [F1]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]Represents the weighted-average price at which shares were sold within a range between $3.65 and $3.725, inclusive. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]The option for 525,825 shares of common stock was granted on 6/6/2013. 1/4 of the option grant was fully vested and exercisable on 6/6/2014, and 1/48 of the option grant vests and becomes exercisable each month thereafter.